Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Kisa

Showing results (1-10 of 14) with videos related to

Pageof 2
Sort By:
The Science of the Total Environment|September 23, 2006
Fluorescent pseudomonads occurring in Macrotermes subhyalinus mound structures decrease Cd toxicity and improve its accumulation in sorghum plantsR Duponnois, M Kisa, K Assigbetse, et al.
Journal of Applied Microbiology|August 24, 2007
Improvement of Cupressus atlantica Gaussen growth by inoculation with native arbuscular mycorrhizal fungiL Ouahmane, M Hafidi, J Thioulouse, et al.
Mycorrhiza|April 26, 2007
Responses of soil microbial catabolic diversity to arbuscular mycorrhizal inoculation and soil disinfectionA P Dabire, V Hien, M Kisa, et al.
The Journal of Dermatology|March 11, 2025
Deucravacitinib in plaque psoriasis: Safety and efficacy through 3 years in Japanese patients in the phase 3 POETYK PSO-1, PSO-4, and LTE trialsAkimichi Morita, Shinichi Imafuku, Yayoi Tada, et al.
The Journal of Dermatology|November 11, 2024
Indirect comparison of deucravacitinib and other systemic treatments for moderate to severe plaque psoriasis in Asian populations: A systematic literature review and network meta-analysisTsen-Fang Tsai, Yayoi Tada, Camy Kung, et al.
The British Journal of Dermatology|October 22, 2024
Deucravacitinib, an oral selective allosteric tyrosine kinase 2 inhibitor, in patients from China mainland, Taiwan and South Korea with moderate-to-severe plaque psoriasis: a phase III randomized clinical trialJianzhong Zhang, Yangfeng Ding, Ping Wang, et al.
Dermatology and Therapy|July 30, 2024
Deucravacitinib Improves Patient-Reported Outcomes in Patients with Moderate to Severe Psoriasis: Results from the Phase 3 Randomized POETYK PSO-1 and PSO-2 TrialsApril W Armstrong, Matthias Augustin, Jennifer L Beaumont, et al.
Dermatology and Therapy|March 6, 2025
Correction to: Deucravacitinib Improves Patient-Reported Outcomes in Patients with Moderate to Severe Psoriasis: Results from the Phase 3 Randomized POETYK PSO-1 and PSO-2 TrialsApril W Armstrong, Matthias Augustin, Jennifer L Beaumont, et al.
The British Journal of Dermatology|January 16, 2024
Deucravacitinib in plaque psoriasis: 2-year safety and efficacy results from the phase III POETYK trialsMark Lebwohl, Richard B Warren, Howard Sofen, et al.
The Journal of Dermatological Treatment|June 30, 2024
Deucravacitinib onset of action and maintenance of response in phase 3 plaque psoriasis trialsNeil J Korman, Richard B Warren, Jerry Bagel, et al.
Pageof 2

Showing results (1-10 of 14) with videos related to

Sort By:
Pageof 2
The Science of the Total Environment|September 23, 2006
Fluorescent pseudomonads occurring in Macrotermes subhyalinus mound structures decrease Cd toxicity and improve its accumulation in sorghum plantsR Duponnois, M Kisa, K Assigbetse, et al.
Journal of Applied Microbiology|August 24, 2007
Improvement of Cupressus atlantica Gaussen growth by inoculation with native arbuscular mycorrhizal fungiL Ouahmane, M Hafidi, J Thioulouse, et al.
Mycorrhiza|April 26, 2007
Responses of soil microbial catabolic diversity to arbuscular mycorrhizal inoculation and soil disinfectionA P Dabire, V Hien, M Kisa, et al.
The Journal of Dermatology|March 11, 2025
Deucravacitinib in plaque psoriasis: Safety and efficacy through 3 years in Japanese patients in the phase 3 POETYK PSO-1, PSO-4, and LTE trialsAkimichi Morita, Shinichi Imafuku, Yayoi Tada, et al.
The Journal of Dermatology|November 11, 2024
Indirect comparison of deucravacitinib and other systemic treatments for moderate to severe plaque psoriasis in Asian populations: A systematic literature review and network meta-analysisTsen-Fang Tsai, Yayoi Tada, Camy Kung, et al.
The British Journal of Dermatology|October 22, 2024
Deucravacitinib, an oral selective allosteric tyrosine kinase 2 inhibitor, in patients from China mainland, Taiwan and South Korea with moderate-to-severe plaque psoriasis: a phase III randomized clinical trialJianzhong Zhang, Yangfeng Ding, Ping Wang, et al.
Dermatology and Therapy|July 30, 2024
Deucravacitinib Improves Patient-Reported Outcomes in Patients with Moderate to Severe Psoriasis: Results from the Phase 3 Randomized POETYK PSO-1 and PSO-2 TrialsApril W Armstrong, Matthias Augustin, Jennifer L Beaumont, et al.
Dermatology and Therapy|March 6, 2025
Correction to: Deucravacitinib Improves Patient-Reported Outcomes in Patients with Moderate to Severe Psoriasis: Results from the Phase 3 Randomized POETYK PSO-1 and PSO-2 TrialsApril W Armstrong, Matthias Augustin, Jennifer L Beaumont, et al.
The British Journal of Dermatology|January 16, 2024
Deucravacitinib in plaque psoriasis: 2-year safety and efficacy results from the phase III POETYK trialsMark Lebwohl, Richard B Warren, Howard Sofen, et al.
The Journal of Dermatological Treatment|June 30, 2024
Deucravacitinib onset of action and maintenance of response in phase 3 plaque psoriasis trialsNeil J Korman, Richard B Warren, Jerry Bagel, et al.
Pageof 2